Cookie Policy         The Babraham Research Campus is also home to The Babraham Institute


  Babraham Bioscience Technologies
        Babraham Research Campus - Cambridge - UK
 

Sponsors

 

MedImmune

 

Neusentis
Babraham Bioscience Technologies Ltd One NucleusCambridge Enterprise

BioInvestment Forum 2014
8th May 2014, Babraham Research Campus, Cambridge

 

Stay Connected INVESTORS

 

VIEW PROGRAMME

 

Who should attend? Venture, Corporate Capital groups and Business Angels

 

- Hear elevator pitches from early stage companies seeking funding (£250K - £5M)

- Poster board exhibition

- 'On the Sofa' with Andy Richards

- Networking

- Guest speaker Jonathan Milner, Abcam, discusses sector specific issues
- Join like minded investors at the exclusive Investor Dinner hosted by Cambridge Enterprise at Homerton College, Cambridge

 

>>>Registration has closed<<<

Companies Confirmed to Present

Abcodia Limited - Funding Required £1.5-5M
Abcodia is pioneering the development of new tests for the early diagnosis and screening of cancer. The company has acquired the exclusive commercial rights to an innovative and well validated algorithm-based test for ovarian cancer screening (ROCA®) which will become the Company’s first product. It has also secured the exclusive commercial access to a 10 year pre-diagnosis collection of serum, derived from 200,000 women, and is now working with CRUK and other partners to generate a further pipeline of IP based around longitudinal profiles of biomarkers that change in line with the pre-diagnosis cancer lifecycle.

 

ABeterno Limited - Funding Required £750K

ABeterno has developed IP in using intracellular proteins as the capture targets for isolation of viable whole cells, enabling their subsequent use in downstream applications. We will use this to exploit a new commercial opportunity in the well established markets for cell separation and live cell imaging, reaching profitability within 2 years and generating substantial returns for investors within 4-5 years via a trade sale in a rapidly growing market sector.

 

ARTERIUS - Funding Required £2.95M
The Company plans to develop and introduce a range of biodegradable drug eluting coronary stents. The unique properties of these stents are that once they have caused vessel remodelling and have been encapsulated in the vessel wall, they biodegrade after a period of 12 to 24 months. The development of fully biodegradable stents that perform the necessary function of remodelling the arterial flow area and then disappear, could make a radical contribution to the priority of tackling a disease that is one of the greatest contributors to mortality in the UK and worldwide.

 

DiagNodus Limited - Funding Required £500-700K
DiagNodus develops new diagnostic approaches in the area of colorectal disease and targets inflammatory bowel disease (IBD) and colorectal cancer (CRC). Clinical endpoints comprise disease detection, monitoring, screening and therapy efficiency assessment. The company has successfully devised and clinically tested a new method for non-invasive colorectal sample collection and a family of biomarker-based diagnostic tests. The company is currently initiating the development of a point of care (POC) version of its test for IBD and prepares to start clinical trials targeting CRC.

 

INDIGIX Limited - Funding Required £3M
INDIGIX
is developing an oral drug to protect the gut wall from the damage caused by Antibiotic Associated Diarrhoea (AAD) and Clostridium difficile Associated Diarrhoea (CDAD).  Formed as an Imperial College spinout in 2010, it is now seeking to raise equity funding of £3m to complete the pre-clinical development of INX201. This is a first-in-class host targeted immuno-modulatory drug that protects the human gut wall from the IL-6 & IL-8 mediated damage caused by gut pathogens.  INX201 can be co-administered with any antibiotic that is given for more than 7 days and it will prevent AAD and CDAD.

 

Mantra Bioscience Limited - Funding Required £370K

Healthcare Associated Infections cost the UK around £1bn per year, despite years of investment.  Research shows that ubiquitous healthcare devices such as blood pressure cuffs and pulse oximeters are crucial causes of infection spread, but a reliance on manual cleaning has been totally ineffective.  Mantra Medical’s objective is to change that forever with our unique products that provide rapid and effective bedside decontamination of blood pressure cuffs and pulse oximeters without relying on manual cleaning.  We have solid IP, related concepts in other medical submarkets, and have initial commercial interest from two large established medical companies.      

 

Miti Biosystems - Funding Required £1.5M
Miti Biosystems is harnessing enzymes from nature to generate highly constrained peptides as therapeutics. Lead compounds hold the promise to combine the best of mAbs with traditional small molecules. Miti's polycyclic peptides are called RiPPs (ribosomally synthesised post-translationally modified peptides) and are amenable to phage display and other diversity methods. The unusual structure, stability, thermodynamically disfavoured bond tensions and novel binding mode of RiPPs open up novel chemical space. As many RiPPs have proven oral bioavailability and cell penetration characteristics in nature, we aim to tap this neglected source of drug-like compounds for Pharma & Biotech

 

NovioSense BV - Funding Required £4M
NovioSense BV is a medical device company founded in 2012 with the aim to develop a new non-invasive glucose sensor for type 1 diabetics. NovioSense has developed a unique platform technology to measure glucose levels in tear fluid in a non-invasive form factor. The glucose in tears have been shown to follow that of glucose in blood and be a clinically representative measure for treatment of diabetes type 1.  NovioSense have developed a pre-clinical laboratory device that can continuously monitor glucose levels in tears and are now seeking investment to continue development into clinical validation.

 

Opal Oncology Limited - Funding Required £600K
Opal Oncology is a drug discovery company based in Cambridge, UK. Opal Oncology is focused on developing novel treatment approaches for an incurable brain cancer called Glioblastoma Multiforme (GBM), which affects 23,000 patients in the West and has orphan disease status with expedited review tracks at major global regulatory agencies such as the US FDA and EMA.


Rare Biotech Limited - Funding Required £1.5M
Rare Biotech is targeting rare diseases and the development of orphan drugs.  We identify, evaluate and develop technologies with therapeutic and commercial potential sourced from both academia and industry.  Development plans are matched with appropriate sources of funding to accelerate the progression of technologies through to the clinic.   Rare Biotech operates a ‘virtual company model’ out-sourcing R&D to maximise the impact of funding. A portfolio of technologies are targeted to provide attractive opportunities for future partners and investment.  Rare Biotech was founded in January 2014 and is currently assembling initial technologies and funding.

 

Vasgen Limited - Funding Required £3.5M
Vasgen Ltd is a biotech start-up based in London, developing a novel platform technology to deliver highly selective inhibitors of the metzincin superfamily of metalloproteinases. By targeting antibodies to the enzyme’s catalytic centre, coined AbIMP® technology, Vasgen intends to overcome the historical problem of target non-selectivity and associated side-effects attributed to chemical inhibitors, thereby offering new possibilities for drug discovery and therapy. Our pathfinding programme has developed the world’s first selective pharmacological inhibitor of ADAM15, a validated and previously intractable anti-angiogenesis and anti-tumour target, as a potential novel therapy to capture significant value in the ophthalmology and cancer markets.

 

Veraz - Funding Required £2.6M

Veraz is an innovation led company that has developed novel workflow management and process quality assurance products and techniques. By first quarter 2015 we will be delivering a revolutionary suite of products that protect patients from poor or absent health care. These products rely on our patented sensor technology which detects what/who/where/when people touch. In a clinical trial we monitored staff compliance to their hand hygiene obligations. We measured compliance rates averaging 20% of those being reported. When we provided instant feedback compliance rates rose by 300%. This year we are also adding to the list of care procedures that the products will support, for example, patient repositioning.

 

Travel and Parking

The nearest train station is Cambridge with taxi services available.
Ample free car parking on site.
The Campus has links with local hotels in and around Cambridge. Contact Us for more information.

 

 

 

Babraham Bioscience Technologies Ltd - Cambridge - United Kingdom